Is LB PHARMACEUTICALS INC (LBRX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.6% / 30% | 4.7% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.6% / 33% | 4.7% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 11.0% / 33% | 83.5% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.6% / 33% | 4.7% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 11.0% / 33% | 83.5% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -15.7% | |
| Return on Assets (ROA) | -10.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$53M |
| Free Cash Flow | -$54M |
| Total Debt | $4M |
| Debt-to-Equity | 1.2 |
| Current Ratio | 41.4 |
| Total Assets | $34M |
Price & Trading
| Last Close | $24.53 |
| 50-Day MA | $23.55 |
| 200-Day MA | $19.70 |
| Avg Volume | 239K |
|
52-Week Range
$13.36
| |
About LB PHARMACEUTICALS INC (LBRX)
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 1 clinical trial for the treatment of bipolar I depression; and in pr clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is LB PHARMACEUTICALS INC (LBRX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), LB PHARMACEUTICALS INC is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is LB PHARMACEUTICALS INC's debt ratio?
LB PHARMACEUTICALS INC's debt ratio is 0.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 11.0%.
What are LB PHARMACEUTICALS INC's key financial metrics?
LB PHARMACEUTICALS INC has a market capitalization of $684M. Return on equity stands at -15.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.